A prospective study of 745 women receiving different regimens of hormone treatment for the cimacteric for a total of 21 736 months was performed. There was a lower incidence of endometrial hyperplasia in biopsy specimens in the women receiving cyclical low-dose oestrogen by mouth than in those receiving cyclical high-dose oestrogen by mouth. The incidence of abnormalities in the women receiving sequential oestrogen and progestogen was lower than in either of these two groups. Among the women receiving subcutaneous oestrogen implants the incidence was higher still, but over half of the abnormal specimens were from women who had not taken their progestogen. The incidence of hyperplasia fell with longer courses of progestogen, and no hyperplasia was found in patients taking progestogen for over 10 days each month.
and we now report on the incidence of abnormal endometrial histology on various regimens of oestrogens and progestogens and on differences in their bleeding pattern.
Patients and methods
Endometrial biopsies were performed in 745 women receiving hormone treatment and attending the menopause research clinic at the Birmingham and Midland Hospital for Women and at the Dulwich Hospital, London. The regimens used were as follows:
Cyclical low-dose oral oestrogens for 3 weeks out of 4-(a) piperazine oestrone sulphate 1-5 mg (Harmogen); (b) oestradiol valerate 1 mg (Progynova); (c) conjugated equine oestrogens 0-625 mg (Premarin); (d) oestriol hemisuccinate 8 mg (Synapause).
Cyclical high-dose oestrogens for 3 weeks out of 4-(a) piperazine oestrone sulphate 3 or 4-5 mg (Harmogen); (b) oestradiol valerate 2 mg (Progynova); (c) conjugated equine oestrogens 1 25 mg (Premarin) .
Sequential oral oestrogens with added progestogen-(a) oestradiol valerate 2 mg daily for 11 days then oestradiol valerate 2 mg and norgestrel 0-5 mg for 10 days, then 7 tablet-free (days (CycloProgynova); (b) mestranol in graded doses daily 12 5-50 eug for 15 days then again with norethisterone 0-75 mg-1i5 mg for 13 days (Syntex Menophase); (c) conjugated equine oestrogens 125 mg for 14 days then again with norgestrel 0 5 mg for 7 days followed by a week without treatment (Prempak); (d) continuous oral oestrogens and a progestogen for 5 or 7 days-usually norethisterone 5 mg daily.
Subcutaneous oestradiol implants 50 mg-with or without 100 mg testosterone-and oral norethisterone 5 mg daily for 5-13 consecutive days monthly.
Endometrial biopsy samples were obtained by vacuum aspiration curettage using either the Rolon curette (Rocket) or the Vabra aspirator (Lewis Laboratories). This was performed six months after the start of treatment and then yearly. Pretreatment samples were obtained routinely only from those women complaining of irregular bleeding. Histological assessment was performed by only T W-E.
Vaginal bleeding was specified as: none, scheduled (bleeding in the week without treatment in cyclical regimens or after courses of progestogen), and unscheduled (bleeding at any other time). Statistical significance was assessed by the x2 test of association or the exact test of significance. The mean age of the patients was 50 2 years.
Results Tables I-IV show (1) (2) (3) (4) (5) (6) (7) (8) of hyperplasia in this group was 14 8°0. The rate of hyperplasia per 1000 months of treatment was unaffected by the type of oestrogen. When progestogens and oestrogens were taken the incidence of hyperplasia was considerably less (1-2o0) , with no hyperplasia shown in the 147 specimens from patients receiving Syntex Menophase after 2402 months of observation. The overall incidence of hyperplasia in patients receiving an oestradiol implant was 14 80' (table II) . Forty-three of these patients, however, did not take any progestogen and their incidence of hyperplasia was 55.8o'. The incidence was only 3O in patients taking 10-day courses of progestogen, and no hyperplasia was found when norethisterone was given for over 10 days. A fourfold table'of the progestogen and non-progestogen groups against normal and abnormal histology showed that there was a significantly lower rate of abnormality among the progestogen users (X2 = 67-32, p < 0-001).
There was a significantly higher incidence of hyperplasia in those patients receiving high-dose cyclical oestrogens compared with the 366 specimens from patients receiving oestrogens and progestogens (p < 0-001). There was also a significantly higher incidence of adenomatous and atypical hyperplasia in those patients receiving only oestrogens (4 00' and 0.60o, p < 001).
There was a significant difference in the incidence of hyperplasia between those women receiving oestradiol implants and in those receiving oral oestrogen and progestogen (-2=43-91, p <0001), but the incidence of hyperplasia in patients taking progestogen for at least 10 days was the same for both regimens. The incidence in those patients who were prescribed Premarin 125 mg alone (table III) was significantly higher than that in those who were prescribed Premarin 1 25 mg and norethisterone (table IV, x2= 8 8052, p < 0-01). The mean duration of treatment was 21 6 months. Table V shows the number of patients receiving cyclical Premarin 1-25 mg in each six-monthly period. The duration of treatment was correlated with endometrial abnormalities. There was a significantly higher incidence of hyperplasia among those women who had received Premarin for over 12 months compared with those who had received it for less (X2 = 6-122, p < 0-02). 114 (640 ). Six patients had hyperplasia: three had cystic hyperplasia, one adenomatous hyperplasia, one atypical hyperplasia, and one adenocarcinoma. The adenocarcinoma occurred in a 64-year-old woman who had no postmenopausal bleeding. She underwent operation, but the hyperplasia in the other five patients was reversed with oestrogen and progestogen preparations.
Discussion
The addition of progestogen to oestrogen treatment to prevent endometrial carcinoma has long been advocated,5-8 since it produces more complete shedding of the endometrium.9 This supposition has recently been challenged.' 0 ' Hence prospective studies should determine the exact risk of oestrogen treatment and the protective effect of progestogens, which two of the retrospective studies giving details of progestogen usage have not done.2 12
The incidence of endometrial carcinoma in women aged 50-60 years is low (28-32/100 000),"3 and many years of observation are required to determine any risk. The incidence of endometrial hyperplasia, which may be a precursor of adenocarcinoma, is much higher, and our study has confirmed the value of progestogens in reducing this incidence. The lower incidence of hyperplasia with added progestogen has been reported,4 1415 but because of the larger number of patients in our study we have been able to show that this occurs on several regimens.
The incidence of hyperplasia fell in women receiving either Premarin 1-25 mg or oestradiol implants when progestogen was added (p <0 001). The incidence of hyperplasia among women receiving oestrogen and progestogen preparations (120') was much less than that among those receiving high-dose cyclical oestrogen (14-8°0). The difference between the equivalent incidences of adenomatous hyperplasia (0 60o and 400°,) was also significant. Greenblatt16 studied 1058 menopausal women who had received oestrogen and progestogen preparations for a total of 9175 years and found only five cases of endometrial carcinoma-lower than the incidence in the general population.
The length of treatment in our study was too short to allow any definite conclusion, but progestogens may reduce the risk of endometrial carcinoma. No cases of endometrial carcinoma occurred in 21 736 months of observation, although we have had four cases referred to us, including a case that has been reported previously,4 but the hormones had been prescribed by others.
There were no cases of hyperplasia among women receiving progestogen for over 10 days monthly and only two cases of hyperplasia among those receiving progestogen for only 10 days. In both these cases the endometrium reverted to normal without any alteration in treatment. The type of oestrogen used does not appear to affect the incidence of hyperplasia. All groups of patients receiving high-dose cyclical oestrogens had an abnormality rate of about five/1000 months of treatment. There was an increased incidence of hyperplasia with longer courses of treatment (table V) . Only women receiving Premarin 1-25 mg were considered in this analysis to eliminate the effect of the different regimens.
The proportion of satisfactory specimens obtained before treatment (640%) was much higher than in our preliminary study.4 This probably reflected a change in policy whereby only patients who were still having periods underwent curettage. Even after rigorous selection our abnormality rate of 50' was much lower than before. 9 Those patients with unscheduled bleeding had the greatest incidence of abnormalities (24-40'). Nevertheless, those with scheduled bleeding or with none had appreciable incidences (5-90% and 9-4%" respectively). This confirms the findings of studies on smaller numbers of patients4 17: bleeding that is regular or absent does not exclude endometrial abnormality.
Our study confirms the value of giving a progestogen for at least 10 days in each cycle in preventing both cystic and adenomatous hyperplasia. Regular endometrial curettage is also advisable, especially for women who are receiving only oestrogens. Our study also shows that the bleeding response during treatment provides no useful guide to the health of the endometrium. 
